Joshua Richter, M.D., is an Associate Professor in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College. He completed residency at St. Vincent’s Hospital – New York Medical College. Dr Richter completed his hematology/oncology fellowship at the Yale Cancer Center. After completing fellowship he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical. In 2018 he joined the Myeloma Division at Mount Sinai Hospital. Dr Richter has been published in numerous oncology journals including NEJM, Blood, and the Journal of Clinical Oncology. He has an interest in immunotherapy, multi-functional antibodies and precision medicine.
Adaptive Biotechnologies, AstraZeneca, BMS, Celgene, Janssen, Karyopharm, Oncopeptides, Secura Bio, Sanofi and X4 Pharmaceuticals.
Episode 2: Choosing the Best Treatment Regimen in RRMM